Stock Alert: Aurobindo Pharma, Highway Infra, NCC, Bata India

Shares of SAIL were banned from F&O trading on 1 October 2026.

Stocks to Watch:

Aurobindo pharmaceutical subsidiary, Acrotech Biopharma Inc., announced the US launch of ADQUEY (difamilast 1%) ointment, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two years and older. The launch marks Acrotech's entry into the US dermatology market. Difamilast was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech Biopharma for commercialisation in the US.

NCC has received two additional orders in September, totalling Rs 500.22 crore. Of the two orders, Rs 224.74 crore pertains to the buildings division, while Rs 275.48 crore pertains to the transportation division.

Highway Infrastructure has entered into a contract agreement with the Uttar Pradesh Expressways Industrial Development Authority for the execution of a work order worth Rs 220.66 crore for the collection of user fees and operation of toll plazas at the Gorakhpur Link Expressway. Additionally, the company has received a Letter of Acceptance (LoA) worth Rs 24.46 crore from the National Highways Authority of India for operations at Velanchettiyur Fee Plaza in Tamil Nadu.

Lemon Tree Hotels announced the opening of Keys Prima by Lemon Tree Hotels in Darjeeling, marking the group's first hotel in the town and further strengthening its presence in West Bengal. The 65-room hotel is managed by the company's subsidiary, Carnation Hotels.

Bata India has appointed Sanjay Rao as Managing Director and Chief Executive Officer. He succeeds Gunjan Shah, who will conclude his tenure after completing his five-year mandate leading the business.

South Indian Bank announced that Mahesh Muralidhar Pai has been appointed as Managing Director and Chief Executive Officer of the bank for a three-year term, effective October 1.

Symbiotec Pharma announced that its wholly owned subsidiary, Knovea Pharmaceutical, has entered into a definitive agreement with a leading global pharmaceutical company, granting the partner exclusive rights to commercialise and distribute two dual-chamber vial-based injectable products in the United States.

Powered by Capital Market - Live News